In a nutshell This study evaluated the effectiveness and safety of BEAM (carmustine, etoposide, cytarabine, and melphalan) chemotherapy before allogeneic hematopoietic cell transplantation (alloHCT; transferring healthy cells from a donor) for relapsed or unresponsive lymphoma. This study concluded that alloHCT with BEAM chemotherapy is an alternative...
Read MoreIn a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...
Read MoreIn a nutshell This study reviewed recent recommendations in the management of patients with diffuse large B cell lymphoma (DLBCL). Some background DLBCL is the most common type of non-Hodgkin lymphoma (NHL). The current standard treatment includes chemotherapy and immunotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin,...
Read More
In a nutshell This phase 3 trial is examining the effectiveness of a combination treatment with panitumumab (Vectibix), leucovorin and fluorouracil after chemotherapy combined with panitumumab in metastatic (spread to other parts of the body) colorectal cancer. The main outcome to be measured is progression-free survival (PFS; time from treatment to...
Read More
In a nutshell This study looked at the safety and effectiveness of axicabtagene ciloleucel (AC; Yescarta) in the treatment of unresponsive B-cell lymphoma. Researchers found that AC is a safe and effective treatment for these patients. Some background B-cell lymphoma is a cancer of cells in the immune system. It is treated with medication that targets...
Read More
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read More
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read More
In a nutshell This study evaluated the impact of early FDG PET/CT scanning on the survival of patients with lymphoma after allogeneic stem cell transplantation (alloSCT). This study concluded that having positive scan results at 3 months after alloSCT may highly predict relapse and poor survival in these patients. Some background An alloSCT is a...
Read MoreIn a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...
Read More
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read More
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read More
In a nutshell This study looked at the safety and effectiveness of ibrutinib (Imbruvica) added to bendamustine (Treanda) and rituximab (Rituxan) in the treatment of unresponsive chronic lymphocytic leukemia. Researchers found that this treatment improved survival in these patients. Some background Chronic lymphocytic leukemia (CLL) is a...
Read More
